Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Promoter Region
80%
Malignant Neoplasm
76%
Phlebothrombosis
60%
Prognostic Factor
60%
Cell-Free DNA
46%
Upper Gastrointestinal Cancer
46%
Venous Thromboembolism
45%
Biological Marker
43%
Pancreas Cancer
36%
Secreted Frizzled-Related Protein 1
33%
Preoperative Chemotherapy
31%
Pulmonary Embolism
30%
Overall Survival
29%
Cancer Diagnosis
29%
Neoplasm
26%
Deep Vein Thrombosis
24%
Radiation Therapy
24%
Prevalence
24%
Odds Ratio
23%
D-Dimer
22%
Esophageal Cancer
22%
Stomach Cancer
22%
Prospective Cohort Study
22%
Gemcitabine
22%
Adenocarcinoma
22%
microRNA
20%
Randomized Controlled Trial
20%
Cholangiocarcinoma
20%
Barrett Esophagus
20%
Postoperative Complication
20%
Plummer-Vinson Syndrome
20%
Cholelithiasis
20%
Prospective Study
20%
Monocyte
20%
Retrospective Study
20%
Leukocyte Activation
20%
Computer Assisted Tomography
19%
Diseases
18%
Neoadjuvant Chemotherapy
17%
Oxaliplatin
16%
Pulmonary Angiography
16%
Hazard Ratio
15%
Biliary Tract Cancer
14%
Cancer Staging
13%
Pancreatic Ductal Adenocarcinoma
12%
Bisulfite
12%
Capecitabine
11%
Epirubicin
11%
Biopsy
10%
Keyphrases
Pancreatic Adenocarcinoma
42%
Promoter Methylation
40%
SFRP1
40%
Blood Biomarkers
26%
Gemcitabine
22%
Prognostic Marker
20%
DNA Promoter Hypermethylation
20%
Gastrointestinal Cancer Patients
20%
Neutrophil Activation Marker
20%
Arteria Lusoria
20%
Distal Cholangiocarcinoma
20%
Pancreatic Ductal Adenocarcinoma
20%
Clinical Target Volume
20%
Endoscopic Surveillance
20%
Surgical Societies
20%
Gastroesophageal Junction Cancer
20%
Preoperative Surgery
20%
Gastroesophageal Adenocarcinoma
20%
Upper Gastrointestinal Cancer
20%
Preoperative Chemotherapy
20%
Cancer Outcomes
20%
Pancreaticobiliary Tract
20%
Cancer Prognostics
20%
Cell-free DNA (cfDNA)
20%
Gastroesophageal Junction
15%
Cox Regression
13%
Absolute Monocyte Count
11%
Plasma microRNA
10%
Geometric Margin
10%
Gross Tumor Volume
10%
Radiotherapy Plan
10%
Bisulfite Treatment
8%
Log-rank Test
8%
Promoter Region
8%
Median Overall Survival
8%
Validation Studies
6%
Endoscopist
6%
Tumor
6%
Compression Ultrasound
6%
BNC1
6%
Validation Cohort
6%
Hypermethylation
6%
Methylation-specific Polymerase Chain Reaction
6%
Tailored Treatment
6%
CDKN2B
6%
Gene-based
6%
Locally Advanced PDAC
6%
Free DNA
6%
Quantitative Methylation-specific PCR (Q-MSP)
5%
Head-and-neck Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
100%
Secreted Frizzled Related Protein 1
53%
Biological Marker
43%
Vein Thrombosis
40%
Pancreas Cancer
33%
Gemcitabine
30%
Disease
23%
Overall Survival
20%
Chemotherapy
20%
Prospective Cohort Study
20%
D Dimer
20%
microRNA
20%
Digestive System Cancer
20%
Cholelithiasis
20%
Randomized Controlled Trial
20%
Bile Duct Carcinoma
20%
Bisulfite
16%
Malignant Neoplasm
13%
Progression Free Survival
10%
Survival Time
10%
Common Bile Duct Stone
8%
Calgranulin
6%
Cancer Staging
6%
Neoplasm
6%
Acute Cholecystitis
5%